menu search

Interactive brokers group to present at barclays global financial services conference

GREENWICH, Conn.--(BUSINESS WIRE)---- $IBKR #Earnings--Interactive Brokers Group, Inc. (Nasdaq: IBKR) announces that its Chairman Thomas Peterffy will...

August 28, 2023, 9:00 am

Altria: this dividend king increased its dividend 4.3% and yields 8.98%

Altria Group is the king of the Dividend Kings, with 54 consecutive years of dividend increases and a dividend yield of 8.98%. MO's future dividend pl...

August 28, 2023, 8:45 am

Panbela to present at h.c. wainwright 25th annual global investment conference

MINNEAPOLIS, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disru...

August 28, 2023, 8:15 am

Hersha hospitality stock soars after buyout deal at 59% premium with ksl capital

Shares of Hersha Hospitality Trust HT, soared 56.7% toward an eight-month high in premarket trading Monday, after the real estate investment trust foc...

August 28, 2023, 8:14 am

Edwards lifesciences to present at the 2023 wells fargo healthcare conference

IRVINE, Calif., Aug. 28, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced it is scheduled to ...

August 28, 2023, 8:10 am

Best reit to buy: american tower vs. crown castle

Cell tower REITs have historically been very good investments. But what's the best pick of the sector? I compare American Tower and Crown Castle and <...

August 28, 2023, 7:57 am

69 ben graham september value stocks: 55 ridiculous buys

“Value ranking looks at the price of a stock relative to intrinsic firm value. Graham Value Stocks match the criteria Benjamin Graham followed." —...

August 28, 2023, 7:52 am

Asic eyes ai: new plan to shield australians from financial scams

Artificial intelligence (AI) may soon assist financial regulators in combating criminals. The Australian Securities and Investments Commission (ASIC) ...

August 28, 2023, 7:09 am

Praxis precision medicines to present analyses of patient-focused, clinically meaningful endpoints from essential1 study of ulixacaltamide in essential tremor at the 2023 mds international congress

BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating gene...

August 28, 2023, 7:00 am

Theravance biopharma to present new ampreloxetine data at the 2023 international congress of parkinson's disease and movement disorders

DUBLIN , Aug. 28, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new amprel...

August 28, 2023, 6:06 am

Evolution ab's unjustified huge discount

Evolution AB presents a risk-reward asymmetry and is 40% undervalued compared to my base case scenario with a fair price of €163. The company does n...

August 28, 2023, 5:19 am

Bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2

– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consisten...

August 27, 2023, 10:15 am

Bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2

– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consisten...

August 27, 2023, 10:15 am

Bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2

– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consisten...

August 27, 2023, 10:15 am

Bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2

– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consisten...

August 27, 2023, 10:15 am

Bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2

– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consisten...

August 27, 2023, 10:15 am

Exelixis: positive pancreatic cancer data brings 2 big catalysts on deck

Phase 3 CABINET study, using CABOMETYX to treat patients with advanced pancreatic cancer and advanced pancreatic neuroendocrine tumors, stopped early ...

August 27, 2023, 6:03 am

7% dividend yield and more at columbia banking, a hidden buy opportunity

Columbia Banking System, the parent of Umpqua Bank, a major regional bank in the northwest, gets a Strong Buy rating today. Positives: dividend yield ...

August 27, 2023, 5:39 am

Self driving comes to san francisco

California regulators vote on allowing self-driving taxis in major cities, presenting a huge market opportunity in the industry. Waymo and Cruise are ...

August 27, 2023, 2:04 am

Esperion presents two clear outcomes study late-breakers at european society of cardiology congress 2023

– In total cardiovascular event analysis, bempedoic acid shows 20% risk reduction in MACE-4 and 17% risk reduction in MACE-3 – – In an analysis ...

August 26, 2023, 3:00 pm


Search within

Pages Search Results: